Change of Director's Interest Notices
Released
Released
Announcement PDF
Appendix 3Y
Change of Director’s Interest Notice
Rule 3.19A.2
Appendix 3Y
Change of Director’s Interest Notice
Information or documents not available now must be given to ASX as soon as available. Information and
documents given to ASX become ASX’s property and may be made public.
Introduced 30/09/01 Amended 01/01/11
Name of entity
Recce Pharmaceuticals Ltd (Company)
ABN
73 124 849 065
We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for
the director for the purposes of section 205G of the Corporations Act.
Name of Director
Dr John Prendergast
Date of last notice
14 December 2023
Part 1 - Change of director’s relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust
Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be
disclosed in this part.
Direct or indirect interest
Direct
Nature of indirect interest
(including registered holder)
N/A
Note: Provide details of the circumstances giving rise to the relevant
interest.
Date of change
14 November 2024
No. of securities held prior to change
306,819 fully paid ordinary shares
2,175,000 unlisted options each exercisable at
$1.56, expiring 22 February 2026
Class
Unlisted options
Number acquired
2,650,000 unlisted options
Number disposed
Nil
Value/Consideration
The options have an estimated value of $0.244
per option. The value per option was
calculated by using the Black Scholes option
valuation methodology.
Note: If consideration is non-cash, provide details and estimated
valuation
+ See chapter 19 for defined terms.
01/01/2011
Appendix 3Y Page 1
Appendix 3Y
Change of Director’s Interest Notice
306,819 fully paid ordinary shares
No. of securities held after change
2,175,000 unlisted options each exercisable at
$1.56, expiring 22 February 2026
2,650,000 unlisted options each exercisable at
$0.80, expiring 14 November 2029
Nature of change
Example: on-market trade, off-market trade, exercise of options, issue
of securities under dividend reinvestment plan, participation in buyback
Issue of unlisted options under the Company’s
Employee Incentive Plan as approved by
shareholders at the Annual General Meeting
held on 6 November 2024.
Part 2 – Change of director’s interests in contracts
Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be
disclosed in this part.
Detail of contract
N/A
Nature of interest
N/A
Name of registered holder
(if issued securities)
N/A
Date of change
N/A
No. and class of securities to which
interest related prior to change
Note: Details are only required for a
contract in relation to which the
interest has changed
N/A
Interest acquired
N/A
Interest disposed
N/A
Value/Consideration
Note: If consideration is non-cash,
provide details and an estimated
valuation
N/A
Interest after change
N/A
Part 3 – +Closed period
Were the interests in the securities or contracts detailed above
traded during a +closed period where prior written clearance
was required?
N/A
+ See chapter 19 for defined terms.
Appendix 3Y Page 2
01/01/2011
Appendix 3Y
Change of Director’s Interest Notice
If so, was prior written clearance provided to allow the trade to
proceed during this period?
N/A
If prior written clearance was provided, on what date was this
provided?
N/A
+ See chapter 19 for defined terms.
01/01/2011
Appendix 3Y Page 3
Appendix 3Y
Change of Director’s Interest Notice
Rule 3.19A.2
Appendix 3Y
Change of Director’s Interest Notice
Information or documents not available now must be given to ASX as soon as available. Information and
documents given to ASX become ASX’s property and may be made public.
Introduced 30/09/01 Amended 01/01/11
Name of entity
Recce Pharmaceuticals Ltd (Company)
ABN
73 124 849 065
We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for
the director for the purposes of section 205G of the Corporations Act.
Name of Director
James Graham
Date of last notice
6 October 2023
Part 1 - Change of director’s relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust
Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be
disclosed in this part.
Direct or indirect interest
Direct and indirect interest
Nature of indirect interest
(including registered holder)
Note: Provide details of the circumstances giving rise to the relevant
interest.
Mr. James Graham is the trustee of the J
Graham Family Trust and a beneficiary of the
trust
Buttonwood Nominees Pty Ltd held on behalf
of Mr James Graham
Date of change
14 November 2024
No. of securities held prior to change
Direct Interest
1. 389,712 Class B Performance Shares
2. 2,250,000 each exercisable at $1.56,
expiring 22 February 2026
Indirect Interest
Mr. James Graham <J Graham Family A/c>
3. 356,250 Class B Performance Shares
Buttonwood Nominees Pty Ltd
4. 6,765,362 fully paid ordinary shares
Class
Unlisted options
Number acquired
3,000,000 unlisted options
+ See chapter 19 for defined terms.
01/01/2011
Appendix 3Y Page 1
Appendix 3Y
Change of Director’s Interest Notice
Number disposed
Nil
Value/Consideration
The options have an estimated value of $0.244
per option. The value per option was
calculated by using the Black Scholes option
valuation methodology.
Note: If consideration is non-cash, provide details and estimated
valuation
Direct Interest
1. 389,712 Class B Performance Shares
2. 2,250,000 each exercisable at $1.56,
expiring 22 February 2026
3. 3,000,000 unlisted options each
exercisable at $0.80, expiring 14
November 2029
No. of securities held after change
Indirect Interest
Mr. James Graham <J Graham Family A/c>
4. 356,250 Class B Performance Shares
Buttonwood Nominees Pty Ltd
5. 6,765,362 fully paid ordinary shares
Nature of change
Example: on-market trade, off-market trade, exercise of options, issue
of securities under dividend reinvestment plan, participation in buyback
Issue of unlisted options under the Company’s
Employee Incentive Plan as approved by
shareholders at the Annual General Meeting
held on 6 November 2024.
Part 2 – Change of director’s interests in contracts
Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be
disclosed in this part.
Detail of contract
N/A
Nature of interest
N/A
Name of registered holder
(if issued securities)
N/A
Date of change
N/A
No. and class of securities to which
interest related prior to change
Note: Details are only required for a
contract in relation to which the
interest has changed
N/A
Interest acquired
N/A
Interest disposed
N/A
+ See chapter 19 for defined terms.
Appendix 3Y Page 2
01/01/2011
Appendix 3Y
Change of Director’s Interest Notice
Value/Consideration
Note: If consideration is non-cash,
provide details and an estimated
valuation
N/A
Interest after change
N/A
Part 3 – +Closed period
Were the interests in the securities or contracts detailed above
traded during a +closed period where prior written clearance
was required?
If so, was prior written clearance provided to allow the trade to
proceed during this period?
N/A
If prior written clearance was provided, on what date was this
provided?
N/A
N/A
+ See chapter 19 for defined terms.
01/01/2011
Appendix 3Y Page 3
Appendix 3Y
Change of Director’s Interest Notice
Rule 3.19A.2
Appendix 3Y
Change of Director’s Interest Notice
Information or documents not available now must be given to ASX as soon as available. Information and
documents given to ASX become ASX’s property and may be made public.
Introduced 30/09/01 Amended 01/01/11
Name of entity
Recce Pharmaceuticals Ltd (Company)
ABN
73 124 849 065
We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for
the director for the purposes of section 205G of the Corporations Act.
Name of Director
Dr Justin Ward
Date of last notice
14 December 2023
Part 1 - Change of director’s relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust
Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be
disclosed in this part.
Direct or indirect interest
Direct
Nature of indirect interest
(including registered holder)
N/A
Note: Provide details of the circumstances giving rise to the relevant
interest.
Date of change
14 November 2024
No. of securities held prior to change
301,444 fully paid ordinary shares
600,000 unlisted options each exercisable at
$1.56, expiring 22 February 2026
Class
Unlisted options
Number acquired
1,000,000 unlisted options
Number disposed
Nil
Value/Consideration
The options have an estimated value of $0.244
per option. The value per option was
calculated by using the Black Scholes option
valuation methodology.
Note: If consideration is non-cash, provide details and estimated
valuation
+ See chapter 19 for defined terms.
01/01/2011
Appendix 3Y Page 1
Appendix 3Y
Change of Director’s Interest Notice
301,444 fully paid ordinary shares
No. of securities held after change
600,000 unlisted options each exercisable at
$1.56, expiring 22 February 2026
1,000,000 unlisted options each exercisable at
$0.80, expiring 14 November 2029
Nature of change
Example: on-market trade, off-market trade, exercise of options, issue
of securities under dividend reinvestment plan, participation in buyback
Issue of unlisted options under the Company’s
Employee Incentive Plan as approved by
shareholders at the Annual General Meeting
held on 6 November 2024.
Part 2 – Change of director’s interests in contracts
Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be
disclosed in this part.
Detail of contract
N/A
Nature of interest
N/A
Name of registered holder
(if issued securities)
N/A
Date of change
N/A
No. and class of securities to which
interest related prior to change
Note: Details are only required for a
contract in relation to which the
interest has changed
N/A
Interest acquired
N/A
Interest disposed
N/A
Value/Consideration
Note: If consideration is non-cash,
provide details and an estimated
valuation
N/A
Interest after change
N/A
Part 3 – +Closed period
Were the interests in the securities or contracts detailed above
traded during a +closed period where prior written clearance
was required?
N/A
+ See chapter 19 for defined terms.
Appendix 3Y Page 2
01/01/2011
Appendix 3Y
Change of Director’s Interest Notice
If so, was prior written clearance provided to allow the trade to
proceed during this period?
N/A
If prior written clearance was provided, on what date was this
provided?
N/A
+ See chapter 19 for defined terms.
01/01/2011
Appendix 3Y Page 3
Appendix 3Y
Change of Director’s Interest Notice
Rule 3.19A.2
Appendix 3Y
Change of Director’s Interest Notice
Information or documents not available now must be given to ASX as soon as available. Information and
documents given to ASX become ASX’s property and may be made public.
Introduced 30/09/01 Amended 01/01/11
Name of entity
Recce Pharmaceuticals Ltd (Company)
ABN
73 124 849 065
We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for
the director for the purposes of section 205G of the Corporations Act.
Name of Director
Ms Michele Keryn Dilizia
Date of last notice
14 December 2023
Part 1 - Change of director’s relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust
Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be
disclosed in this part.
Direct or indirect interest
Direct
Nature of indirect interest
(including registered holder)
N/A
Note: Provide details of the circumstances giving rise to the relevant
interest.
Date of change
14 November 2024
No. of securities held prior to change
2,707,080 fully paid ordinary shares
577,212 Class B Performance Shares
Class
1,500,000 unlisted options each exercisable at
$1.56, expiring 22 February 2026
Unlisted options
Number acquired
1,600,000 unlisted options
Number disposed
Nil
Value/Consideration
The options have an estimated value of $0.244
per option. The value per option was
calculated by using the Black Scholes option
valuation methodology.
Note: If consideration is non-cash, provide details and estimated
valuation
+ See chapter 19 for defined terms.
01/01/2011
Appendix 3Y Page 1
Appendix 3Y
Change of Director’s Interest Notice
2,707,080 fully paid ordinary shares
No. of securities held after change
577,212 Class B Performance Shares
1,500,000 unlisted options each exercisable at
$1.56, expiring 22 February 2026
1,600,000 unlisted options each exercisable at
$0.80, expiring 14 November 2029
Nature of change
Example: on-market trade, off-market trade, exercise of options, issue
of securities under dividend reinvestment plan, participation in buyback
Issue of unlisted options under the Company’s
Employee Incentive Plan as approved by
shareholders at the Annual General Meeting
held on 6 November 2024.
Part 2 – Change of director’s interests in contracts
Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be
disclosed in this part.
Detail of contract
N/A
Nature of interest
N/A
Name of registered holder
(if issued securities)
N/A
Date of change
N/A
No. and class of securities to which
interest related prior to change
Note: Details are only required for a
contract in relation to which the
interest has changed
N/A
Interest acquired
N/A
Interest disposed
N/A
Value/Consideration
Note: If consideration is non-cash,
provide details and an estimated
valuation
N/A
Interest after change
N/A
Part 3 – +Closed period
+ See chapter 19 for defined terms.
Appendix 3Y Page 2
01/01/2011
Appendix 3Y
Change of Director’s Interest Notice
Were the interests in the securities or contracts detailed above
traded during a +closed period where prior written clearance
was required?
If so, was prior written clearance provided to allow the trade to
proceed during this period?
N/A
If prior written clearance was provided, on what date was this
provided?
N/A
N/A
+ See chapter 19 for defined terms.
01/01/2011
Appendix 3Y Page 3
Appendix 3Y
Change of Director’s Interest Notice
Rule 3.19A.2
Appendix 3Y
Change of Director’s Interest Notice
Information or documents not available now must be given to ASX as soon as available. Information and
documents given to ASX become ASX’s property and may be made public.
Introduced 30/09/01 Amended 01/01/11
Name of entity
Recce Pharmaceuticals Ltd (Company)
ABN
73 124 849 065
We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for
the director for the purposes of section 205G of the Corporations Act.
Name of Director
Dr Alan Dunton
Date of last notice
14 December 2023
Part 1 - Change of director’s relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust
Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be
disclosed in this part.
Direct or indirect interest
Direct
Nature of indirect interest
(including registered holder)
Danerius LLC an entity controlled by Dr
Dunton
Note: Provide details of the circumstances giving rise to the relevant
interest.
Date of change
14 November 2024
No. of securities held prior to change
126,819 fully paid ordinary shares
1,125,000 unlisted options each exercisable at
$1.56, expiring 22 February 2026
Class
Unlisted options
Number acquired
2,250,000 unlisted options
Number disposed
Nil
Value/Consideration
The options have an estimated value of $0.244
per option. The value per option was
calculated by using the Black Scholes option
valuation methodology.
Note: If consideration is non-cash, provide details and estimated
valuation
+ See chapter 19 for defined terms.
01/01/2011
Appendix 3Y Page 1
Appendix 3Y
Change of Director’s Interest Notice
126,819 fully paid ordinary shares
No. of securities held after change
1,125,000 unlisted options each exercisable at
$1.56, expiring 22 February 2026
2,250,000 unlisted options each exercisable at
$0.80, expiring 14 November 2029
Nature of change
Example: on-market trade, off-market trade, exercise of options, issue
of securities under dividend reinvestment plan, participation in buyback
Issue of unlisted options under the Company’s
Employee Incentive Plan as approved by
shareholders at the Annual General Meeting
held on 6 November 2024.
Part 2 – Change of director’s interests in contracts
Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be
disclosed in this part.
Detail of contract
N/A
Nature of interest
N/A
Name of registered holder
(if issued securities)
N/A
Date of change
N/A
No. and class of securities to which
interest related prior to change
Note: Details are only required for a
contract in relation to which the
interest has changed
N/A
Interest acquired
N/A
Interest disposed
N/A
Value/Consideration
Note: If consideration is non-cash,
provide details and an estimated
valuation
N/A
Interest after change
N/A
Part 3 – +Closed period
Were the interests in the securities or contracts detailed above
traded during a +closed period where prior written clearance
was required?
N/A
+ See chapter 19 for defined terms.
Appendix 3Y Page 2
01/01/2011
Appendix 3Y
Change of Director’s Interest Notice
If so, was prior written clearance provided to allow the trade to
proceed during this period?
N/A
If prior written clearance was provided, on what date was this
provided?
N/A
+ See chapter 19 for defined terms.
01/01/2011
Appendix 3Y Page 3
Appendix 3Y
Change of Director’s Interest Notice
Rule 3.19A.2
Appendix 3Y
Change of Director’s Interest Notice
Information or documents not available now must be given to ASX as soon as available. Information and
documents given to ASX become ASX’s property and may be made public.
Introduced 30/09/01 Amended 01/01/11
Name of entity
Recce Pharmaceuticals Ltd (Company)
ABN
73 124 849 065
We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for
the director for the purposes of section 205G of the Corporations Act.
Name of Director
Alistair McKeough
Date of last notice
6 October 2023
Part 1 - Change of director’s relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust
Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be
disclosed in this part.
Direct or indirect interest
Indirect
Nature of indirect interest
(including registered holder)
Finn Frist Pty Ltd as trustee for the AZM
Superannuation Fund of which Mr McKeough
is a director and shareholder of the trustee and
a beneficiary of the trust (Finn Frist Pty Ltd)
Note: Provide details of the circumstances giving rise to the relevant
interest.
Date of change
No. of securities held prior to change
Amabel Pty Limited as trustee for the
McKeough Family Trust of which Mr
McKeough is a director of the trustee and a
beneficiary of the trust (Amabel Pty Limited)
14 November 2024
Finn Frist Pty Ltd
1. 25,961 fully paid ordinary shares
Class
Amabel Pty Limited
2. 1,125,000 unlisted options each
exercisable at $1.56, expiring 15
November 2027
Unlisted options
Number acquired
1,000,000 unlisted options
Number disposed
Nil
+ See chapter 19 for defined terms.
01/01/2011
Appendix 3Y Page 1
Appendix 3Y
Change of Director’s Interest Notice
Value/Consideration
Note: If consideration is non-cash, provide details and estimated
valuation
The options have an estimated value of $0.244
per option. The value per option was
calculated by using the Black Scholes option
valuation methodology.
Finn Frist Pty Ltd
1. 25,961 fully paid ordinary shares
No. of securities held after change
Amabel Pty Limited
2. 1,125,000 unlisted options each
exercisable at $1.56, expiring 15
November 2027
3. 1,000,000 unlisted options each
exercisable at $0.80, expiring 14
November 2029
Nature of change
Example: on-market trade, off-market trade, exercise of options, issue
of securities under dividend reinvestment plan, participation in buyback
Issue of unlisted options under the Company’s
Employee Incentive Plan as approved by
shareholders at the Annual General Meeting
held on 6 November 2024.
Part 2 – Change of director’s interests in contracts
Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be
disclosed in this part.
Detail of contract
N/A
Nature of interest
N/A
Name of registered holder
(if issued securities)
N/A
Date of change
N/A
No. and class of securities to which
interest related prior to change
Note: Details are only required for a
contract in relation to which the
interest has changed
N/A
Interest acquired
N/A
Interest disposed
N/A
Value/Consideration
Note: If consideration is non-cash,
provide details and an estimated
valuation
N/A
Interest after change
N/A
+ See chapter 19 for defined terms.
Appendix 3Y Page 2
01/01/2011
Appendix 3Y
Change of Director’s Interest Notice
Part 3 – +Closed period
Were the interests in the securities or contracts detailed above
traded during a +closed period where prior written clearance
was required?
If so, was prior written clearance provided to allow the trade to
proceed during this period?
N/A
If prior written clearance was provided, on what date was this
provided?
N/A
N/A
+ See chapter 19 for defined terms.
01/01/2011
Appendix 3Y Page 3
Share your feedback
Discover